An expanded portfolio of standardised in vitro diagnostic reagents has enhanced the work of the clinical flow cytometry laboratory, as recently published examples in a Beckman Coulter ClearLLab Casebook illustrate.
Flow cytometric immunophenotyping (FCI) techniques are an important element in aiding the diagnosis and follow-up of leukaemia and non-Hodgkin’s lymphoma (NHL). “The overriding benefit over immunohistochemistry (IHC) techniques is the ability to assess numerous markers simultaneously,” says Jeannine Holden, Chief Medical Officer and Vice President of Scientific and Medical Affairs at Beckman Coulter.
. Flow cytometry’s ability to show even subtle differences in antigen density makes it possible to distinguish and characterise aberrant cells that may be present in minute quantities.1 In Europe, flow cytometry is already used for patients presenting with disease in the bone marrow and/or peripheral blood, and increasingly used to study lymph nodes
Characterising normal and aberrant cells
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.
Register
